Histone deacetylase inhibitors: a survey of recent patents

Bibliography

• MILLER TA: Patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2004) 14(61:791–804.
   Google Scholar
• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics 2000. CA Cancer J. Clin. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• MM A, MASSA A, ROTILI D et al: Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. (2005) 25:261–309.
   PubMedGoogle Scholar
• MCLAUGHLIN F, LA THANGUE N: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol (2004) 68:1139–1144.
   PubMed Web of Science ®Google Scholar
• MET S, HO AD, MAHLKNECHT U: Role of histone deacetylase inhibitors in the treatment of cancer. Int. J. Oncol (2004) 25:1509–1519.
   PubMedGoogle Scholar
• BHALLA KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. (2005) 23(17):3971–3993.
   PubMed Web of Science ®Google Scholar
• ROSATO R, GRANTS: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs (2004) 13:21–38.
   PubMedGoogle Scholar
• MARKS PA, RICHON VM, BRESLOW R, RIFKIND RA: Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. (2001) 13:477–483.
   PubMed Web of Science ®Google Scholar
• KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trial. Expert Opin. Investig. Drugs (2002) 11:1695–1713.
   PubMed Web of Science ®Google Scholar
• HESS-STUMPP H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell Biol. (2005) 84:109–121.
   PubMed Web of Science ®Google Scholar
• DRUMMOND DC, NOBLE CO, KIRPOTIN DB et al.: Clinical development of histone deacetylase inhibitors as anticancer agents. Ann. Rev. Pharmacol Toxicol (2005) 45:495–528.
   PubMed Web of Science ®Google Scholar
• PIEKARTZ R, BATES S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. (2004) 10(19):2289–2298.
   PubMedGoogle Scholar
• DE RUIJTER AJ, VAN GENNIP AH, CARON HN, KEMP S, VAN KUILENBURG AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. (2003) 370:737–749.
   Google Scholar
• GRAY GG, EKSTROM TJ: The human histone deacetylase family. Exp. Cell. Res. (2001) 262:75–83.
   PubMed Web of Science ®Google Scholar
• HAGGARTY SJ, KOELLER KM, WONG JC, GROZINGER CM, SCHREIBER SL: Domain-selective small molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Nail Acad. Sci. USA (2003) 100(8):4389–4394.
   PubMed Web of Science ®Google Scholar
• BALI P, PRANPAT M, BRADNER J et al: Inhibition ofhistone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. (2005) 280(29):6729–6734.
   Google Scholar
• GAO L, CUETO MA, ASSELBERGS F, ATAOJA P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family./ Biol. Chem. (2002) 277:25748–25755.
   PubMed Web of Science ®Google Scholar
• FINNIN MS, DONIGIAN JR, COHEN A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188–193.
   PubMed Web of Science ®Google Scholar
• SOMOZA JR, SKENE RJ, KATZ BA et al.: Structural snapshots of human HDAC8 provide insights into the Class I histone deacetylases. Structure (2004) 12:1325–1334.
   PubMed Web of Science ®Google Scholar
• VANNINI A. VOLPARI C, FILOCAMO Get al.: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA (2004) 101:15064–15069.
   Google Scholar
• YOSHIDA M, MATSUYAMA A, KOMATSU Y, NISHINO N: From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. (2003) 10:2351–2358.
   PubMedGoogle Scholar
• MONNERET C: Histone deacetylase inhibitors. Eur. J. Med. Chem. (2005) 40:1–13.
   PubMed Web of Science ®Google Scholar
• MILLER TA, WITTER DJ, BELVEDERE S: Histone deacetylase inhibitors. J. Med. Chem. (2003) 46:5097–5116.
   PubMed Web of Science ®Google Scholar
• GOMEZ-VIDAL JA, CAMPOS J, MARCHAL JA et al.: Actual targets in cytodifferentiation cancer therapy. Curr. Topics Med. Chem. (2004) 4:175–202.
   PubMedGoogle Scholar
• REMISZEWSKI SW: Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Disc. Dev. (2002) 5:487–99.
   PubMed Web of Science ®Google Scholar
• MARKS PA, MILLER T, RICHON VM: Histone deacetylases. Curr. Opin. PharmacoL (2003) 3:344–351.
   PubMed Web of Science ®Google Scholar
• WEINMANN H, OTTOW E: Recent advances in medicinal chemistry of histone deacetylase inhibitors. Ann. Rep. Med. Chem. (2004) 39:186–196.
   Google Scholar
• YANG K, LOU B: Molecular diversity of hydroxamic acids: part I. Solution- and solid-phase synthesis. Mini Rev. Med. Chem. (2003) 3:349–360.
   Google Scholar
• LOU B, YANG K: Molecular diversity of hydroxamic acids: part II. Potential therapeutic applications. Mini Rev. Med. Chem. (2003) 3:609–620.
   PubMed Web of Science ®Google Scholar
• CURTIN ML: Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors. Curr. Opin. Drug Discov. Devel. (2004) 7: 848–868.
   PubMedGoogle Scholar
• SHABBEER S, CARDUCCI MA: Focus on deacetylation for therapeutic benefit. Investig. Drugs (2005) 8:144–154.
   Google Scholar
• KELLY WK, CONNOR OA, KRUG L, CHIAO J, HEANEY M, CURLEY T: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. Clin . Oncol. (2005) 23(17):3923–3931.
   Google Scholar
• KELLY WK, MARKS PA: Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. (2005) 2(3):150–157.
   PubMedGoogle Scholar
• ATADJA P, GAOL, KWON P et al.: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. (2004) 64:689–695.
   PubMed Web of Science ®Google Scholar
• PLUMB JA, FINN PW, WILLIAMS RJ et al.: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. MoL Cancer Ther. (2003) 2:721–728.
   PubMed Web of Science ®Google Scholar
• VANHAECKE T, PAPELEU P, ELAUT G, ROGIERS V: Trichostatin A - like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. (2004) 11:1629–1643.
   PubMed Web of Science ®Google Scholar
• FREY RR, WADA CK, GARLAND RB et al.: Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg-. Med. Chem. Lett. (2002) 12:3443–3447.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, MATSUURA A, KOUKETSU A. NAKAGAWA H, MIYATA N: Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Bioorg-. Med. Chem. Lett. (2005) 15:331–335.
   Google Scholar
• CHEN B, PETUKHOV PA, JUNG M et al.: Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg-. Med. Chem. Lett. (2005) 15:1389–1392.
   PubMed Web of Science ®Google Scholar
• NEWMARK HL, LUPTON JR, YOUNG CW: Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. (2001) 78:1–5.
   Google Scholar
• DIGIUSEPPE JA, WENIG LJ, YU KH et al.: Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (1999) 13:1243–1253.
   PubMed Web of Science ®Google Scholar
• GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBOJ. (2001) 20:6969–6978.
   PubMed Web of Science ®Google Scholar
• LU Q, WANG D-S, CHEN C-S, HU Y-D,CHEN C-S: Structure-based optimization of phenylbutyratederived histone deacetylase inhibitors. J. Med. Chem. (2005) 48:5530–5535.
   PubMedGoogle Scholar
• SUZUKI T, ANDO T, TSUCHIYA K, FUKAZAWA N, SAITO A: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. (1999) 42:3001–3003.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN F, LA THANGUE NB: Histone deacetylase inhibitors in psoriasis therapy. Curr. Drug Targets Inflamm. Allergy (2004) 3:213–219.
   PubMedGoogle Scholar
• ARTS J, DE SCHEPER S, VAN EMELEN K: Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr. Med. Chem. (2003) 10:2343–2350.
   PubMed Web of Science ®Google Scholar
• BERTOS NR, WANG AH, YANG XJ: Class II histone deacetylases: structure, function, and regulation. Biochem. Cell. Biol. (2001) 79:243–252.
   PubMed Web of Science ®Google Scholar
• UNGERSTEDT JS, SOWA Y, XU WS et al.: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Nail. Acad. Sci. USA (2005) 102(3):673–678.
   PubMed Web of Science ®Google Scholar